Phase II trial of tumour infiltrating lymphocytes in patients with metastatic melanoma

Trial Profile

Phase II trial of tumour infiltrating lymphocytes in patients with metastatic melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs LN 144 (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Iovance Biotherapeutics; Lion Biotechnologies Inc
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 16 Sep 2015 According to a Lion Biotechnologies media release, updated results from this trial were presented at the American Association for Cancer Research Inaugural International Cancer Immunotherapy Conference.
    • 16 Sep 2015 Updated results from this trial were published in a Lion Biotechnologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top